>>Signaling Pathways>> Immunology/Inflammation>> Innate Immunity>>Colchicine-d6

Colchicine-d6

Catalog No.GC47117

콜히친-d6은 콜히친이라는 라벨이 붙은 중수소입니다. 콜히친은 튜불린 억제제이자 미세소관 교란제입니다. 콜히친은 3 nM의 IC50으로 미세소관 중합을 억제합니다. 콜히친은 또한 α3 글리신 수용체(GlyR)의 경쟁적 길항제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Colchicine-d6 Chemical Structure

Cas No.: 1217651-73-4

Size 가격 재고 수량
1 mg
US$540.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Video

Colchicine-d6 is intended for use as an internal standard for the quantification of colchicine by GC- or LC-MS. Colchicine is an inhibitor of microtubule polymerization (IC50 = 3.2 μM) that binds to tubulin, which disrupts spindle formation during mitosis.1 It inhibits growth of MCF-7 human breast carcinoma cells with an IC50 value of 13 nM.1 Colchicine has anti-inflammatory activity, inhibiting neutrophil motility and activity when used at a dose of 5 μmol/kg in a mouse model of gout and preventing the deposition of uric acid.2,3

1.Martino, G.D., Regina, G.L., Coluccia, A., et al.Arylthioindoles, potent inhibitors of tubulin polymerizationJ. Med. Chem.47(25)6120-6123(2004) 2.McCarty, D.J.Urate crystals, inflammation, and colchicineArthritis Rheum.58(2)S20-S24(2008) 3.Chia, E.W., Grainger, R., and Harper, J.L.Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: A rationale for use of low-dose colchicineBr. J. Pharmacol.153(6)1288-1295(2008)

리뷰

Review for Colchicine-d6

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Colchicine-d6

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.